FIO2=0.8

PreclinicalSmall molecule

AAssiut University

FIO2=0.8 is one of 7 small molecule programs targeting Surgical Site Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Surgical Site InfectionCompleted

Surgical Site InfectionPreclinical

Completed

Competition

Competitive Landscape

11 competitors in Surgical Site Infection

#DrugCompanyPhaseTrials

Keflex

Eli Lilly

Approved

2 2

Vancocin

HHikma Pharmaceuticals LLC

Approved

5 3

Betadine

BBecton, Dickinson and Company

Approved

1 4

Ancef

BBaxter Healthcare Corporation

Preclinical

2 5

Garamycin

SSchering-Plough

Preclinical

1 6

Standard Antibiotic Prophylaxis

WWestern Galilee Hospital-Nahariya

Preclinical

1 7

FIO2=0.8

AAssiut University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Surgical Site Infection1 trial

High vs Low Inspired Intraoperative Oxygen Concentration on the Incidence of Surgical Site Infection in Hepatobiliary Surgeries

Completed·AAssiut University·Preclinical·NCT06108791·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FIO2=0.8. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FIO2=0.8 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FIO2=0.8. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssiut University

FIO2=0.8

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Surgical Site Infection1 trial

References

Drug Info

Quick Facts

Related News